O2h Ventures

Entrepreneur who began his career at PA Consulting's Life Sciences team and co-founded Oxygen Healthcare (acquired by Piramal in 2013). He co-founded the o2h Group including o2h Ventures, o2h Discovery, and o2h Co-Work Labs, and is involved in over 20 UK biotech companies. He holds a Biochemistry degree from Keele and an MBA from Cambridge.

Medicinal chemist with over 25 years of major pharma experience (Sanofi-Aventis, AstraZeneca) and author of over 55 publications and patents. He leads scientific evaluation of investments at o2h Ventures and serves as CSO of Opal Oncology.

Spent 17 years as an equity research analyst and fund manager, building a UK Income fund to over £1bn AUM, following 6 years as a Technology Consultant at PA Consulting. He holds a Cambridge MA in Natural Sciences and an MBA from London Business School.

Scientist and biotech entrepreneur with over 15 years of drug discovery experience, founder and former CEO of NeoPhore Ltd and former COO of PhoreMost. He holds a bachelor's from Harvard Extension School with expertise in cancer and metabolic disease genetics.

Leads global operations at o2h covering life-science and technology investments and oversees the o2h Shirish Research Centre in Ahmedabad. Previously at Piramal Group, he holds a PhD from Ohio University and completed a post-doc at Harvard Medical School.

o2h Group's Marketing Manager leading a marketing team focused on brand, advertising, content, digital marketing, and PR. He previously worked as a digital marketer for tech SMEs and a seed-stage ecommerce startup.

Has over 25 years of biotech, pharmaceutical, and venture investing experience and is CEO and co-founder of Exonate, spun out of Nottingham University. She holds a medical degree from Birmingham University and was awarded an OBE in 2008.

Has over 18 years of post-doctoral experience in therapeutic discovery across biotech, consultancy, and CRO organizations. Previously EVP of Business Development at Domainex, she holds an MSc from Nottingham, a PhD in Cell Biology from Cambridge, and an MBA from the Open University.

Set up FreeMedic PLC in 1993, now known as UCL Business PLC, one of the UK's most prolific technology groups. He was involved in numerous university licenses and spinouts, including PolyMASC Pharmaceuticals and Stanmore Implants Worldwide.

Leads fundraising for the o2h human health EIS and SEIS funds, with a background in business development across financial services, EIS/SEIS analysis, financial media, and renewable energy financing. He holds a degree in French and European Studies from Aston University.

Cancer researcher and entrepreneur who founded Horizon Discovery in 2007, growing it into the UK's fastest-growing biotech and taking it public on the London Stock Exchange in 2014. He completed post-doctoral training at Johns Hopkins University.

Senior compliance professional and former regulator with 28 years of experience, including compliance leadership roles at Brevan Howard and a boutique investment bank. He founded Tetractys Partners LLP and Tetractys Ireland Limited, compliance consultancies serving asset managers and financial firms.

Senior scientist with over 15 years of experience who leads the scientific due diligence process at o2h Ventures, specializing in pre-clinical research evaluation. She holds a PhD in Neuroscience from the Brain Research Institute in Zurich.

Executive search professional with nearly two decades of experience across the UK, USA, and India, including roles at Egon Zehnder, Michael Page, and BSG Team Ventures. She founded Tamarind and holds economics degrees from Delhi University and Lancaster University.

Manages the Investor Relations function at o2h Ventures, overseeing investor communications, reporting, and relationship management. She previously worked at UHBW NHS Trust in Bristol and Tata Consultancy Services.

Synthetic chemist with over 17 years of experience who leads technical vetting of chemical assets at o2h Ventures. Previously a senior scientist at Piramal Discovery Solutions, he holds a PhD in Organic Chemistry from Kadi Sarva University.

Marketing Manager at o2h Ventures overseeing the marketing lifecycle, including content across blogs, social media, and websites. She previously worked in finance and accounting and holds an MBA from PDEU University.

Founder and CEO of Sentinel Oncology, a medicinal chemist with over 25 years of industry experience at firms including Pfizer, Millennium Pharmaceuticals, and Astex Therapeutics. He is a named inventor on over 50 patents and publications.

Senior Fund Operations Manager and EA to the CEO at o2h Ventures, acting as liaison for fund matters and monitoring deal flow. She has prior operations and international business management experience and a BBA from ICFAI University.

Deal Flow Manager at o2h Ventures involved in managing and expanding the investment portfolio. He holds a master's in biotechnology and previously worked as a healthcare research analyst.

Chemist with over two decades of experience in preclinical drug discovery who oversees all projects in the USA region. He earned a master's from Gujarat University, a PhD in India, and post-doctoral experience at the University of Glasgow, with prior roles at Alembic, Evotec, o2h, and Piramal.

Experienced biotech and pharmaceutical leader with executive and board roles, a founder with over 40 patents and publications who has secured over $6 billion in deals across M&A, licensing, and collaborations spanning oncology, CNS, and other areas.